Sabby Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sabby Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-593	Closed	-$6.61M	–	199
2018 Q1	$6.61M	Buy	593 +346	+140%	+$41.4K	0.79%	21
2017 Q4	$2.95M	Buy	+247	New	+$30.1K	0.27%	44
2017 Q3	–	Sell	-800	Closed	-$9.73M	–	229
2017 Q2	$9.73M	Sell	800 -2,017	-72%	-$235K	0.64%	24
2017 Q1	$34.2M	Buy	2,817 +1,231	+78%	+$159K	1.84%	13
2016 Q4	$19.4M	Buy	+1,586	New	+$194K	1.13%	20
2016 Q1	–	Sell	-152	Closed	-$2.9M	–	377
2015 Q4	$2.9M	Hold	152	–	–	0.16%	96
2015 Q3	$2.38M	Buy	+152	New	+$27.7K	0.1%	138
2014 Q1	–	Sell	-389	Closed	-$5.18M	–	286
2013 Q4	$5.18M	Sell	389 -727	-65%	-$87.2K	0.33%	49
2013 Q3	$13M	Buy	1,116 +727	+187%	+$79.8K	0.84%	31
2013 Q2	$3.59M	Buy	+389	New	+$37.5K	0.24%	77

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sabby Management's ALXN Position: Q2 2016 in Review

Sabby Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 27,856 shares — an estimated $3.88M sold.

Sabby Management first reported a position in ALXN in Q2 2015 and held it in 4 quarters. The position peaked at $7.72M in Q3 2015. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

Sabby Management reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Sabby Management sold 27,856 Alexion Pharmaceuticals shares in Q2 2016, an estimated $3.88M.
Sabby Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 4 quarters.
Sabby Management's Alexion Pharmaceuticals position peaked at $7.72M in Q3 2015.
533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.